Methotrexate and misoprostol against misoprostol alone for early medical abortion: comparative study

Vaginal mifepristone oral misoprostol have proven to be highly effective medical abortion methods and are used widely in in modern countries. The objective of this study is to compare the efficacy for two medical abortion regimens used in one clinic setting misoprostol alone, intramuscular methotrexate and vaginal misoprostol. An intervention study was conducted on a total of 100 randomly selected women with gestations of first-trimester pregnancy, who sought a missed abortion. Study population was assigned as two groups, the first was subjected to vaginal administration of Misoprostol and the second was subjected to EV1 injection of methotrexate and self-administration of vaginal misoprostol After 72h. All patients were followed up for recording any side effects of the drugs, progress of abortion and if there was any need for surgical interference [manual vacuum aspiration [MVA] or dilatation and curettage. Success rate of the methotrexate regimen was 80% and did not differ significantly from the misoprostol regimen that had success rate of 84%.In this real-use setting, the use of misoprostol in combination with methotrexate or alone for the missed abortion termination are both safe and effective methods without serious side effects

immunohistochemical expression of vascular endothelial growth factor in serous ovarian tumors

Tumor specimens from 30 cases of serous tumors were stained immunohistochemically using monoclonal antibodies to vascular endothelial growth factor [VEGF] and factor VIII [FVIII] and avidin- biotin peroxidase method [Neomarker, USA]. There was a correlation between the expression of VEGF, microvessel density, patient's age, histologic grade, bilaterality, tumor stage, presence of ascitis and lymph node involvement. The results showed that ovarian serous tumors showed higher VEGF and FVIII expression in malignant tumors than in benign and borderline tumors. This expression was significantly correlated with microvessel density counts [MVD], tumor stage, presence of ascitis and lymph node involvement. No correlation was found with the architectural grade, patient's age or bilaterality. The expression of VEGF may be a good prognostic indicator for patients with ovarian serous carcinomas and also may be useful as a predictor for patients at high risk for metastasis and/or recurrence and to guide the decision of an additional therapy for surgery